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OBJECTIVES: The aims of the Online Latin American Survey of Anaphylaxis (OLASA) were to identify the main
clinical manifestations, triggers, and treatments of severe allergic reactions in patients who were seen by allergists
from July 2008 to June 2010 in 15 Latin American countries and Portugal (n = 634).
RESULTS: Of all patients, 68.5% were older than 18 years, 41.6% were male, and 65.4% experienced the allergic
reaction at home. The etiologic agent was identified in 87.4% of cases and predominantly consisted of drugs
(31.2%), foods (23.3%), and insect stings (14.9%). The main symptom categories observed during the acute episodes
were cutaneous (94.0%) and respiratory (79.0%). The majority of patients (71.6%) were treated initially by a
physician (office/emergency room) within the first hour after the reaction occurred (60.2%), and 43.5% recovered in
the first hour after treatment. Most patients were treated in an emergency setting, but only 37.3% received
parenteral epinephrine alone or associated with other medication. However, 80.5% and 70.2% were treated with
corticosteroids or antihistamines (alone or in association), respectively. A total of 12.9% of the patients underwent
reanimation maneuvers, and 15.2% were hospitalized. Only 5.8% of the patients returned to the emergency room
after discharge, with 21.7% returning in the first 6 hours after initial treatment.
CONCLUSION: The main clinical manifestations of severe allergic reactions were cutaneous. The etiologic agents
that were identified as causing these acute episodes differed according to age group. Following in order: drugs
(31.2%), foods (23.3% and insect stings (14.9%) in adults with foods predominance in children. Treatment provided
for acute anaphylactic reactions was not appropriate. It is necessary to improve educational programs in order to
enhance the knowledge on this potentially fatal emergency.
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INTRODUCTION
Anaphylaxis is defined as a serious, rapid onset, systemic
allergic reaction that may cause death.1-5 The diagnosis is
based primarily on clinical history, and clinical criteria for
accurate and early identification of anaphylaxis have
recently been established.1
The lifetime prevalence of anaphylaxis from all triggers is
estimated to range from 0.05% to 2.6%. Data on anaphylaxis
prevalence and incidence are sparse, often inaccurate and
underestimates the true incidence of anaphylaxis. The
absence of a universal consensus on the definition of
anaphylaxis, inadequate International Classification of
Diseases (ICD) codes, and incorrect use of the terms
‘prevalence’ and ‘incidence’ in reports of anaphylaxis are
reasons for the discrepancies in these findings.5-14
The triggers of anaphylaxis are represented by the
following three general agents: foods, medications, and
insect stings. These agents vary in prevalence according to
the age of the studied population, the study design, and the
geographic area. Foods are the most common causes of
anaphylaxis in childhood, whereas medications and insect
stings are more common causes in adults. Other, less
common, causes in children and adults include latex,
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immunotherapy-related reactions, exercise, cold and idio-
pathic causes.5-14
Although anaphylaxis is a severe acute reaction, fatalities
due to anaphylaxis are rare. It is estimated that between 0.33
and 3 deaths per 1,000,000 people occur per year.7,8,12-15 The
prompt recognition of symptoms that potentially place
patients at increased risk of severe anaphylaxis is man-
datory for successful treatment and decrease death rate.6
Concomitant diseases, such as asthma or other chronic
respiratory diseases (especially those that are severe or
uncontrolled), cardiovascular disease and mastocytosis are
associatedwith the risk of life-threatening or fatal anaphylaxis.
The use of b-blockers and angiotensin-converting enzyme
inhibitors increase the severity of anaphylaxis, and b-blockers
potentially make anaphylaxis more difficult to treat.6
Long-term treatment of anaphylaxis must be based on the
identification of precipitating factors and the establishment
of preventive measures to reduce the risk of a new
anaphylactic episode. All guidelines mention that epinephr-
ine as the only effective first aid treatment for anaphylaxis,
but it is not usually administered soon enough after the
onset of symptoms or after the exposure to an offending
agent.7,11,15-18
Recently, Worm et al. proposed a pan-European registry
of severe allergic reactions to obtain information about
triggering allergens, aggravating factors, patient demo-
graphics and medical care.19 It was proposed that the data
of all registries in Europe be collected to allow physicians to
promote knowledge on anaphylaxis.19 Data on anaphylaxis
in the Latin American region are scant. The objectives of the
Online Latin American Survey of Anaphylaxis (OLASA)
were to evaluate the main clinical manifestations, triggers,
and treatment of patients with severe allergic reactions who
were seen by allergists.
MATERIALS AND METHODS
A platform to collect information for OLASA (Encuesta/
Denu´ncia de Anafilaxia en Iberoame´rica online) was
developed by the Latin American Society of Allergy,
Asthma and Immunology (SLAAI). The data referred to
patients who were seen by allergists and who presented
with severe allergic reactions from July 2008 to June 2010.
Attending allergists filled in a standardized OLASA ques-
tionnaire which was composed by 45 questions regarding
the current episode and past episodes (triggering agent,
clinical features, place of reaction, treatment received, place
where reaction occurred, evolution of the current episode
after treatment, frequency of episodes among others. This
questionnaire, which was originally developed and vali-
dated in Portuguese,20 was translated into Spanish and was
available online at the SLAAI website.21
A total of 634 patients were registered from 15 countries:
Venezuela (29.1%), Brazil (28.3%), Argentina (26.3%), Mexico
(3.6%), Chile (2.4%), Colombia (2.2%), Uruguay (2.2%),
Ecuador (2.1%), Cuba (1.3%), Portugal (1.3%), Nicaragua
(0.06%), Bolivia (0.06%), Paraguay (0.05%), Peru (0.05%),
Panama (0.01%), and the Dominican Republic (0.01%).
The results were presented as the simple frequency of
positive answers relative to the total number of valid
responses.
The study protocol was approved by the Ethics
Committee of the Federal University of Sa˜o Paulo, Sa˜o
Paulo, Brazil.
RESULTS
A total of 634 patients who were treated for systemic
allergic reactions were enrolled in the study. The demo-
graphic characteristics showed a slight predominance of
females (56.4%) with ages ranging from 1 to 97 years,
stratified as follows: 8.0% were younger than 4 years old,
4.6% were 4-8 years old, 6.8% were 8-12 years old, 9.8%
were 12-18 years old, 42% were 18-40 years old, and 26.5%
were older than 40 years. An acute episode occurred at
home in 65.4% of the cases. Table 1 shows the triggering
agents assumed by patients for the most recent episode,
with 87.4% identifying a trigger as drugs (31.2%), foods
(23.3%) or insect stings (14.8%).
Table 2 shows the major clinical manifestations reported
by patients. There was a significant predominance of
cutaneous symptoms (pruritus and angioedema), followed
by respiratory (dyspnea), cardiovascular (tachycardia), and
gastrointestinal (nausea and dysphagia) symptoms.
Most patients (80.5%) had the current acute severe allergic
epsiode treated in an emergency setting and the remaining
at the place where the reaction occurred. The time to
administration of emergency treatment was variable, with
up to 15 minutes reported by 23.4% of patients, 15-30
minutes in 26.9%, 30-60 minutes in 19.9% and more than 60
minutes or unknown in 29.8%. With regard to symptom
improvement, 43.5% of the patients observed improvement
of their symptoms in the first hour after treatment, 45.1%
observed improvement within six hours, and 11.2%
reported improvement after six hours.
Isolated or associated medications that were used to treat
acute episodes were recognized by 63.9% of the patients and
included systemic corticosteroids (oral or injectable) in
80.5% of the patients, antihistamines (oral or injectable) in
70.2%, and epinephrine (subcutaneous or intramuscular) in
37.3%. A total of 12.9% of the patients required resuscitation
while under hospital care.
After treatment, 67.3% of the patients were discharged
from the emergency room as completely asymptomatic,
18.6% went home with medication, and 15.2% were
hospitalized. Some patients (5.8%) needed to return to the
hospital due to clinical impairment, which occurred at
different times after discharge: 8.7% returned in the first
hour, 13.0% returned between 1 and 6 hours, 45.7% returned
between 6 and 24 hours, and 32.6% returned after 24 hours.
A history of previous acute severe allergic episodes was
reported by 46.2% of the patients. Between 1 and 3 episodes
were reported by 80.3%, 15.9% had 4-10 episodes, and 4.3%
had more than 10 episodes. Time intervals between
episodes was variable, at 15 to 29 days (7.5%), 30 to 60
days (8.7%), 2 to 6 months (6.2%), 6 to 12 months (15.2%) or
more than a year (37.3%). Based on the severity of previous
episodes, 19.7% reported more intense episodes, while
39.8% reported no change. Nevertheless, 32.6% of the
patients required hospital assistance, and 5.0% were
hospitalized.
When patients were discharged from the emergency
room, only 19.5% received orientation on prevention of
future attacks and to search for specialized treatment.
DISCUSSION
This is the first study to evaluate data from Latin American
patients as registered by their attending allergists in an online
survey. Patients were assisted in emergency rooms for severe
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acute allergic episodes by non-specialists who characterized
the episodes as anaphylactic reactions. This condition could
be a study limitation. However, all patients were evaluated
by specialists and had the diagnoses confirmed before data
were included in OLASA.1-5
Establishing prevalence and/or incidence rates was not the
aim of this study. These indexes are usually based on data
collected from Emergency Medical Services systems, emer-
gency department visits, hospital admissions, visits to aller-
gists, medical records obtained from resident populations of a
specific area, and analysis of epinephrine auto-injector
prescriptions. Each of these information sources has potential
limitations because none of the themwill cover 100% of cases.7
Almost 69% of the patients were older than 18 years, which
may explain the higher prevalence of drugs, food and insect
stings as triggers of anaphylactic reactions. However, as
observed by other authors, the prevalence of particular
triggers changes according to patient age. Foods, predomi-
nantly cow’s milk, were more prevalent triggers among
patients younger than 4, followed by insect stings and drugs
(antibiotics). Among patients older than 8, the predominant
causes were drugs (non steroidal anti-inflammatory agents
and antibiotics) followed by foods (fish and seafood) and
insect stings (bees andwasps) (Table 1). A retrospective review
of 601 patients admitted to a reference service for evaluation of
an acute episode of anaphylaxis showed the following trigger
Table 1 - Main triggering agents for severe allergic reactions, according to the age of patients, registered in the Online
Latin American Survey on Anaphylaxis.
Agents Age (year)
1-4
N=51
(%)
4-8
N=29
(%)
8-12
N=43
(%)
12-18
N=62
(%)
18-40
N=266
(%)
. 40
N=168
(%)
Total
N=634
(%)
Drugs - total 5
(9.8)
2
(6.9)
10
(23.3)
20
(31.7)
88
(33.1)
73
(43.5)
198
(31.2)
NSAIDs 1
(1.9)
1
(3.4)
6
(14.0)
19
(30.6)
73
(27.4)
44
(26.2)
144
(22.7)
Antibiotics 4
(7.8)
1
(3.4)
4
(9.3)
- 12
(4.5)
15
(8.9)
36
(5.6)
Others - - - 1
(1.6)
1
(0.3)
11
(6.5)
12
(1,9)
Local anesthetics - - - - 2
(0.7)
3
(1.8)
5
(0,8)
Food - total 24
(47.1)
9
(31.0)
6
(14.0)
8
(12.9)
62
(23.3)
39
(23.2)
148
(23.3)
Fish/seafood 1
(1.9)
3
(10.3)
1
(2.3)
4
(6.5)
37
(14.0)
22
(13.1)
68
(10.7)
Cow’s milk/derivatives 14 (27.5) 2
(6.9)
1
(2.3)
- 1
(0.3)
2
(1.2)
20
(3.2)
Fruits 2
(3.9)
- 2
(4.7)
1
(1.6)
7
(2.6)
5
(2.9)
20
(3.2)
Wheat* - 1
(3.4)
1
(2.3)
2
(3.2)
12
(4.5)
3
(1.8)
19
(92.9)
Peanuts - 2
(6.9)
- - 4
(1.5)
3
(1.8)
9
(1.4)
Eggs 6
(11.8)
- - - - 1
(0.6)
7
(1.1)
Nuts - 1
(3.4)
1
(2.3)
1
(1.6)
1
(0.3)
3
(1.8)
7
(1.1)
Manioc - - 2
(4.7)
- - 1
(0.6)
3
(0.4)
Corn 1
(1.9)
- - 2
(3.2)
- - 3
(0.4)
Insects - total 13
(25.5)
13
(44.8)
10
(23.3)
7
(11.3)
32
(12.0)
19
(11.3)
94
(14.8)
Bees 2
(3.9)
4
(13.8)
6
(14.0)
7
(11.3)
16
(6.0)
12
(7.1)
47
(2.2)
Ants 9
(17.6)
8
(27.6)
1
(2.3)
- 10
(3.8)
1
(0.6)
29
(4.6)
Wasps 2
(3.9)
1
(3.4)
3
(7.0)
- 6
(2.3)
6
(3.6)
18
(2.8)
Immunotherapy - 1
(3.4)
4
(9.3)
4
(6.5)
4
(1.5)
2
(1.2)
15
(2.4)
Latex - - - 2
(3.2)
6
(2.3)
1
(0.6)
9
(1.4)
Exercise - - - 1
(1.6)
2
(0.7)
2
(1.2)
5
(0.8)
Iodinated contrasts - - - - 1
(0.3)
2
(1.2)
3
(0.4)
*wheat contaminated with acari.
NSAIDs - non steroidal anti-inflammatory drugs.
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distribution: idiopathic (59%), food (22%) and medication
(11%).23 In our study, there was a lower prevalence of
idiopathic anaphylaxis (17.8%), but the differences in age
between sample populations could contribute to the contrast-
ing observations. Food allergies are more common among
children, whereas drug and hymenoptera venom allergies are
more common among adults.9-15,22
Cutaneous symptoms predominated (94%) among patients
registered in OLASA, most commonly pruritus (54.2%) and
angioedema (52.0%). In a medical record review of patients
with anaphylaxis from a private university-affiliated allergy
clinic, 87% presented with urticaria and/or angioedema.22
The next most common symptoms were respiratory (79%),
mainly dyspnea (73.1%), which is similar to the level of 59%
reported previously.23 Cardiovascular symptoms were the
third most commonly reported symptoms among patients
(33%with syncope and dizziness), which is similar to the rate
observed among our patients (40.1%), along with palpitation
(58.3%). The clinical picture of patients in OLASA demon-
strated that almost all patients presented cutaneous symp-
toms in addition to other organ involvement, in agreement
with the definition of anaphylaxis.1-4
Although most reactions occurred at home, 60.2% of the
patients were treated in the hospital, with 43.5% treated
within the first hour of the reaction. However, few received
appropriate treatment, considering that parenteral epi-
nephrine is recommended by international guidelines as
the only effective first aid treatment for anaphylaxis if it is
administered soon after the onset of symptoms or after
exposure to an offending trigger.7,11,15,17,18,24,25 In this study,
only 37.3% of the patients received epinephrine (subcuta-
neous or intramuscular) alone or in association with
antihistamines (oral or parenteral) and/or systemic corti-
costeroids (oral or parenteral).
A questionnaire was sent to 52 Brazilian physicians
working in emergency rooms to verify their medical skills
in dealing with anaphylaxis and knowledge on refractory
shock, biphasic reactions and management of patients on b-
blockers. Adrenaline was the first choice in 63.4% of the
cases, mostly via subcutaneous injections, although the site
of injection was not indicated by 52% of the physicians.
Corticosteroid injections ranked second in treatment pre-
valence. Glugacon was mentioned only once as a therapeu-
tic alternative for patients on b-blockers. The biphasic
anaphylactic reaction was not known by 75% of the
physicians. This study highlights the educational deficien-
cies of physicians on duty in emergency rooms to manage
anaphylaxis.26
After treatment, patients were kept in the emergency
room for observation, and most were discharged without
medication. Only 15.2% of the patients required hospita-
lization after emergency room treatment. This rate is in
agreement with the average reported by Clark &
Camargo, which found the rate of hospital admission
after emergency room attendance to range from 3% to
41%.11,13 An emerging concern is that admission rates
vary across studies, mainly due to heterogeneous criteria
for admission and the index applied. For example, the
incidence of hospitalization has been reported to range
from 5.6 per 100,000 to 11.05 per 100,000 hospital
discharges.27-29
Biphasic anaphylaxis is the recurrence of symptoms
within 72 hours with no further exposure to the allergen.
It is estimated to occur in between 1% and 20% of cases,
depending on the study,30-32 and its management is similar
to the treatment of anaphylaxis. In our study, we observed
that 5.8% of patients could be characterized as having
biphasic anaphylaxis because they returned to the emer-
gency room due to symptoms after discharge, which
happened in the first 6 hours for 21.7% of the patients.
Although 46% of the patients had a previous episode of
anaphylaxis, which was considered less severe in 40.5% of
the cases, only 19.5% had received orientation on the
prevention of future episodes and referred to allergy clinics
for treatment.
Our findings are alarming because even though anaphy-
laxis is a potentially fatal medical emergency, the therapeu-
tic and educational approach toward it in Latin America is
not appropriate. Knowledge of clinical manifestations and
triggers are crucial to establish strategies for preventing and
treating these episodes. Educational programs for general
practitioners, pediatricians, and allied health professionals
are necessary to enhance the knowledge of this emergency
condition.
Table 2 - Clinical manifestations during acute severe
allergic reactions (% of each system involved).
Clinical manifestation N %
Cutaneous 596 94.0
Pruritus 323 54.2
Urticaria 81 13.4
Erythema 29 4.9
Angioedema
Lips 305 52.0
Eyelids 118 19.8
Larynx 65 10.9
Face 28 4.7
Tongue 16 2.7
Glotis 12 2.0
Hands 11 1.8
Ears 8 0.7
Generalized 6 0.1
Testicle 3 0.05
Uvula 3 0.05
Respiratory system 501 79.0
Dyspnea 366 73.1
Suffocation 38 7.6
Cough 32 6.4
Hoarseness 29 5.8
Wheezing 26 5.2
Chest tightness 18 3.6
Rhinitis 18 3.6
Nasal congestion 14 2.8
Respiratory arrest 4 0.08
Stridor 4 0.08
Cardiovascular system 254 40.1
Palpitations 148 58.3
Dizziness 48 18.9
Syncope 33 13.0
Lipothymy 25 9.8
Gastrointestinal system 193 30.4
Nausea 71 36.8
Difficulty swallowing 62 32.1
Vomiting 24 12.4
Abdominal cramps 20 10.4
Diarrhea 11 5.7
Sphincter relaxation 2 1.0
Epigastralgia 2 1.0
Dysphagia 2 1.0
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APPENDIX
The Latin American Anaphylaxis Working Group comprises:
Argentina: Maria Laura Alassia, Dora Arab, Edgardo Azua, Gloria
Bandin, Miriam Bercoff, Maria Eugenia Bessone, Pedro Hector
Borthaburu, Ce´sar Martin Bozzola, Adriana Monica Bracaccini,
Raimundo Matias Camps, Silvana Paola Cardinali, Carlos Carignano,
Gonzalo Chorzepa, Dario Colombaro, Mabel Cuello, Alicia De Falco,
Monica Silvia De Gennaro, Juan Antonio Doglia, Pablo Fasano, Jorge
Carlos Lujan Ferreyra, Roberto Festa, Fernando Luis Gambarte, Patricia
Garnero, Mario Ceferino Ge´e, Hugo Ghiani, Nora Giovino, Maximiliano
Gomez, Toma´s Victoriano Herrero, Maria Del Carmen Imwinkelried,
Edgardo Jares, Nestor Sergio Kahanovsky, Ivan Kriunis, Silvina Noemi
Lisis de Wilson, Cecilia Lucini, Ana Maria Maldonado, Adriana Marcipar,
Elsa Mindel, Hector Moise´s, Juan Moura, Ernesto Mun˜oz, Julio Cesar
Orellana, Roberto Jorge Pozo, German Dario Ramon, Daniela Sacerdote,
Monica Sandra Sanabria, Wenceslao Sanchez de la Veja, Laura Sasia,
Luis Sayago, Debora Seigelshifer, Roberto Gustavo Serrano, Marcelo
Dante Strass, Olga Teresa Vazquez, Anahı´ Ya´n˜ez; Bolivia: Antonio
Lopez, Alfredo Mendonza, Monica Sea; Brazil: Manoel Alves, Leandro
Britto, Herberto Jose´ Chong Neto, Regina DiGesu, Luis Felipe Ensina,
Fa´tima Fernandes, Mario Geller, Hermila Guedes, Fa´bio Kuschnir, Marta
Machado, Alexandre Miyake, Charles Kirov Naspitz, Celso Eduardo
Olivier, Hevertton Santos, Lucia Jasse Santos, Muller Tim, Vanessa
Gonzaga Tava; Chile: Ana Maria Agar Mun˜oz, Ramo´n Canala-
Echevarria, Enzo Espinola, Maria Antonieta Guzman, Maria Angelica
Marinovic, Valentina Parada, Tamara Perez, Erna Ripoll, Paola Toche;
Colombia: Ingrid Bissinger, Eduardo De Zubiria, Rodolfo Jaller Raad,
Maria Victoria Morena, Carlos Serrano; Cuba: Mirta Alvarez, Osvaldo
Batista Rojas, Raul La´zaro Castro, Raquel Garcia, Olimpio Rodriguez;
Dominican Republic: Andres Socias; Equator: Ivan Cherrez Ojeda,
Jose Luis Gonzalez Acun˜a, Rolendio Palacios, Ivan Tinoco, Rommel
Valdivieso, Manuel Eduardo Viteri, Paul Wilches, John Haboud
Zambrano, Edison Vicente Zapata Venegas; Mexico: Rodolfo Celio
Murillo, Jose Refugio Enriquez Salazar, Mercedes Gomez, AryaYannel
Gonza´lez-Gonza´lez, Luis Enrique Hernandez, Rosa Elena Huerta, Blanca
Morfin, Gerardo Mortera, Adriana Elizabeth Pen˜a Rued, Noel
Rodriguez, Hector Manuel Ruiz Dias, Nora Hilda Segura, Hector
Solorio, Jose Enrique Soria, Ana Maria Vegas, Toma´s Velarde;
Nicaragua: Guissele Urbina Palacios; Panama: Diva Almillategui;
Paraguay: Jaime Alberto Guggiari Doutreleau, Manuel Ratti, Hector
Ratti Sisa; Peru: Ricardo Farfan; Portugal: Angela Gaspar, Eva Gomes,
Rodrigo Rodrigues-Alves; Uruguay: Graciela Castro, Grettel Morena,
Juan Francisco Schuhl; Venezuela: Feres Abou Khair.
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